Chesterfield Royal Hospital, Chesterfield, UK.
University of Sheffield, Sheffield, UK, UK.
Clin Med (Lond). 2021 Jan;21(1):e71-e76. doi: 10.7861/clinmed.2020-0614. Epub 2020 Dec 18.
Antibiotic stewardship during the COVID-19 pandemic is an important part of a comprehensive strategy to improve patient outcomes and reduce long-term adverse effects secondary to rising antibiotic resistance. This report describes a quality improvement project which incorporates the use of procalcitonin (PCT) testing to rationalise antibiotic prescribing in patients with suspected or confirmed COVID-19 at Chesterfield Royal Hospital. Data were collected from 118 patients with a total of 127 PCT levels checked over a period of 20 days. Each PCT level was correlated with the subsequent antibiotic outcome as well as the result of the COVID-19 PCR swab. Results indicate that antibiotics were either never started or were stopped within 48 hours in 72% of COVID-confirmed cases with a PCT less than 0.25 μg/L. Our findings suggest that procalcitonin testing, when used in combination with thorough clinical assessment, is a safe, simple and sustainable way of reducing antibiotic use in COVID-19.
在 COVID-19 大流行期间,抗生素管理是改善患者预后和减少因抗生素耐药性上升而导致的长期不良影响的综合策略的重要组成部分。本报告描述了一个质量改进项目,该项目结合了降钙素原 (PCT) 检测,以合理使用抗生素治疗切斯特菲尔德皇家医院疑似或确诊 COVID-19 的患者。在 20 天的时间里,从 118 名患者中收集了总共 127 次 PCT 水平检查的数据。每个 PCT 水平都与随后的抗生素结果以及 COVID-19 PCR 拭子的结果相关。结果表明,在 PCT 水平低于 0.25μg/L 的 COVID-19 确诊病例中,72%的患者的抗生素从未开始使用或在 48 小时内停止使用。我们的研究结果表明,降钙素原检测与彻底的临床评估相结合,是一种安全、简单且可持续的减少 COVID-19 中抗生素使用的方法。